Immune checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4 inhibitors, function by blocking immunosuppressive signals and alleviating the negative regulation of T cells, thereby restoring their anti-tumor activity (Bagchi et al., 2021). This evidence concerns the gene CD274 and neoplasm.